ranitidine sold brand name zantac among others medication used decrease stomach acid commonly used treatment peptic ulcer disease gastroesophageal reflux disease given mouth injection muscle injection vein september probable carcinogen nnitrosodimethylamine ndma discovered ranitidine products number manufacturers resulting april ranitidine withdrawn united states market suspended european union australia due concerns confirmed nationwidewhich population study ranitidine increased risk liver lung gastric pancreatic cancer increased overall cancer risk p common side effects include headaches pain burning given serious side effects may include liver problems slow heart rate pneumonia potential masking stomach also linked increased risk clostridium difficile ranitidine histamine receptor antagonist works blocking histamine thus decreasing amount acid released cells ranitidine discovered england came commercial use world health organizations list essential still available generic medication via internet withdrawn regulator request markets including united discontinued globally according commonly prescribed medication united states million prescriptions vs nearly million years ranitidine discontinued globally according contraindicated due excess cancer risk ready availability antagonist ppi alternatives adverse effects ranitidine reported events clinical trials rare reports made ranitidine causing malaise dizziness somnolence insomnia vertigo severely ill elderly patients cases reversible mental confusion agitation depression hallucinations arrhythmias tachycardia bradycardia atrioventricular block premature ventricular beats also drugs receptor blocker class medicines potential cause vitamin deficiency secondary reduction foodbound vitamin elderly patients taking receptor antagonists likely require supplementation taking blockers may also reduce absorption drugs azole antifungals calcium carbonate require acidic addition multiple studies suggest use receptor antagonists ranitidine may increase risk infectious diarrhoea including travellers diarrhoea study found suppressing acidmediated breakdown proteins ranitidine may lead elevated risk developing food drug allergies due undigested proteins passing gi tract sensitisation occurs patients take agents develop higher levels immunoglobulin e food whether prior antibodies even months discontinuation elevated level ige patients still found studymedical citation needed cholestatic hepatitis liver failure hepatitis jaundice noted require immediate discontinuation blood tests reveal increase liver enzymes eosinophilia although rare instances severe cases hepatotoxicity may require liver ranitidine histamine receptor antagonists may increase risk pneumonia hospitalised may also increase risk communityacquired pneumonia adults thrombocytopenia rare known side effect druginduced thrombocytopenia usually takes weeks months appear may appear within hours drug intake sensitised individual typically platelet count falls normal thrombocytopenia may associated neutropenia rash including rare cases erythema multiforme rare cases hair loss vasculitis relief symptoms due use ranitidine exclude presence gastric malignancy addition kidney liver impairment ranitidine must used caution avoided patients porphyria may precipitate children use gastric acid inhibitors associated increased risk development acute gastroenteritis communityacquired cohort analysis including neonates reported association blocker use increased incidence necrotizing enterocolitis verylowbirthweight vlbw addition sixfold increase mortality necrotizing enterocolitis infection sepsis pneumonia urinary tract infection reported patients receiving ranitidine cohort analysis vlbw ranitidine may return false positive result commercial urine drug screening kits testing drugs september us food drug administration fda learned ranitidine medicines including products sold brand name zantac contained nitrosamine impurity called nnitrosodimethylamine ndma classified probable human carcinogen low health canada announced assessing ndma requested manufacturers stop distribution ranitidine products canada ndma levels products found health canada announced ranitidine drugs recalled sandoz canada apotex inc pro doc limit√©e sanis health inc sivem pharmaceuticals european medicines agency ema started european unionwide review ranitidine medicines request european october us fda observed thirdparty laboratory using higher temperatures tests detect nitrosamine impurities ndma generated added heat higher temperatures recommended using gas spectrometry method test ndma valsartan angiotensin ii receptor fda stated recommends using liquid chromatographyhigh resolution mass spectrometry lchrms testing protocol test samples lchrms testing method use elevated temperatures shown presence much lower levels ndma ranitidine medicines reported thirdparty laboratory international regulators using similar lcms testing methods also shown presence low levels ndma ranitidine fda provided additional guidance using another lcms method based triplequadrupole ms september sandoz issued precautionary distribution stop medicines containing followed days later recall ranitidine hydrochloride capsules united italian medicines agency recalled ranitidine uses active pharmaceutical ingredient saraca federal union german associations pharmacists arzneimittelkommission der deutschen apotheker published list recalled therapeutic goods administration november fda stated tests found levels ndma ranitidine nizatidine similar one may typically ingest common foods grilled smoked fda also stated simulated gastric fluid model tests simulated intestinal fluid model tests indicated ndma formed exposed acid stomach normal fda advised companies recall ranitidine testing shows levels ndma acceptable daily intake nanograms per day parts per million time indicated levels ndma found medicines still exceeded agencys acceptable december fda asked manufacturers ranitidine nizatidine products expand ndma testing include lots medication making available april new fda testing evaluation prompted information thirdparty laboratories confirmed ndma levels increase ranitidine even normal storage conditions ndma found increase significantly samples stored higher temperatures including product may exposed distribution handling testing also showed level ndma increases ranitidine medication conditions may raise ndma level acceptable daily intake ema completed issued euwide review end month european commission suspended ranitidine products august ema provided guidance marketing authorization holders avoiding presence nitrosamine impurities asked review chemical biological human medicines presence nitrosamines test products september fda issued guidance control nitrosamine impurities human implementation plan issued february september apotex recalled overthecounter ranitidine tablets sold united states walmart rite aid retailers along cvs removed zantac generics october medicines healthcare products regulatory agency united kingdom uk issued drug alert ranitidine proactively communicate recall hospitals pharmacies dispensing practices retailers wholesalers included zantacbranded along generic preparations ranitidine teva uk rosemont pharmaceuticals omega pharma limited galpharm international perrigo company creo pharma limited tillomed laboratories otc concepts ltd relonchem ltd noumed life sciences ltd medreich accord medley pharma medreich october department health social care united kingdom issued supply distribution alert oral formulations october sanofi recalled overthecounter zantac united states perrigo issued worldwide recall dr reddys issued recall ranitidine products united novitium pharma recalled ranitidine hydrochloride capsules november aurobindo pharma amneal pharmaceuticals american health packaging golden state medical supply precision dose recalled lots ranitidine tablets capsules december glenmark pharmaceutical inc usa recalled lots ranitidine january appco pharma llc northwind pharmaceuticals recalled lots ranitidine tablets february american health packaging recalled lots ranitidine tablets manufactured amneal april fda requested manufacturers market withdrawal meaning ranitidine products would available prescription overthecounter sale april committee medicinal products human use chmp european medicines agency recommended suspension ranitidine medicines european union presence low levels june ranitidine manufacturer requested reexamination chmps april december ema confirmed recommendation suspend ranitidine medicines european uk national health service nhs web site december said ranitidine currently available uk globally yet known whether available july solara active pharma sciences supplies ranitidine active pharmaceutical ingredient api said mitigated risks formation ndma manufacturing ranitidine api company granted revised certificate european directorate quality medicines healthcare proves api complies european rules october accord healthcare considering possible reintroduction ranitidine glaxosmithkline sanofi teva said plans reintroduce ranitidine competitive reversible inhibitor action histamine histamine receptors found gastric parietal cells results decreased gastric acid secretion gastric volume reduced hydrogen ion ranitidines acidlowering effect pronounced basal nocturnal acid secretion foodstimulated acid secretion additional indirect effects ranitidine decreased pepsin secretion increased nitratereducing bacterial oral absorption protein binding metabolism major metabolite urine ranitidine noxide represents less dose metabolites ranitidine include ranitidine soxide desmethyl ranitidine halflife elimination normal renal function ranitidine taken orally halflife taken intravenously halflife generally hours patient normal kidney function normal creatinine clearancemedical citation needed patients kidney dysfunction halflife may increase excretion primary route excretion addition orally administered dose collected urine unabsorbed drug elderly population plasma halflife ranitidine prolonged hours secondary decreased kidney function causing decreased general studies pediatric patients aged one month years shown significant differences pharmacokinetic parameter values comparison healthy adults correction made body ranitidine first prepared england john bradshaw summer ware research laboratories allen hanburys part former glaxo development response first class histamine receptor antagonist cimetidine developed sir james black smith kline french launched united kingdom tagamet november companies eventually merged glaxosmithkline gsk following sequence mergers acquisitions starting integration allen hanburys ltd glaxo form glaxo group research ultimately merger glaxo wellcome smithkline beecham ranitidine result rational drugdesign process using fairly refined model histamine receptor quantitative structureactivity relationships glaxo refined model replacing imidazole ring cimetidine furan ring nitrogencontaining substituent developed ranitidine ranitidine found farimproved tolerability profile ie fewer adverse drug reactions longerlasting action times activity cimetidine ranitidine affinity cimetidine causes fewer side effects blockers famotidine nizatidine significant ranitidine introduced worlds biggestselling prescription drug needed subsequently largely superseded effective protonpump inhibitor ppi class drugs omeprazole becoming biggestselling drug many yearscitation needed omeprazole ranitidine compared study people severe inflammation erosions ulcers oesophagus treated omeprazole healed within eight weeks compared given ranitidine addition omeprazole group reported earlier relief heartburn september probable carcinogen nnitrosodimethylamine ndma discovered ranitidine products number manufacturers resulting recalls april withdrawn united states market suspended europe australia preparations ranitidine products include oral tablets mg effervescent tablets injectable doses specific ranitidine product preparations available overthecounter otc various countries united kingdom loweststrength tablet available purchase without australia packs containing seven doses tablet available supermarkets small packs tablets schedule pharmacy medicinesmedical citation needed larger doses pack sizes require prescriptionmedical citation needed united states tablets available otc since zantac marketed us india sold brand name rantac httpsenwikipediaorgwikiranitidine